For following the competition: what moved in each program, several studies read as one move.
- blinatumomab
- revumenib
- Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512
- + 11 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Precursor Cell Lymphoblastic Leukemia-Lymphoma to watchlistEvery Monday by email · turn it off any timePro · free during the beta